# BioROSA Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biorosa-technologies

- Industry: Biotechnology
- Headquarters: Belmont, US
- Website: www.biorosa.com
- Latest round: Seed (Jun 14, 2018)
- Investors on record: 1

## About

BioROSA Technologies Inc. specializes in developing innovative blood tests for early detection of Autism Spectrum Disorder (ASD) in children, enhancing timely interventions to improve developmental outcomes.Founded in 2018 in Belmont, US, BioROSA Technologies Inc. focuses on diagnostic solutions for Autism Spectrum Disorder. The company has completed 2 deals, with the most recent funding round being a Venture Debt round in July 2019, raising USD 0.45 mn.BioROSA Technologies specializes in the development of a broad-spectrum blood test designed to detect Autism Spectrum Disorder (ASD) in children as young as 18 months. The core product uses a simple blood draw to analyze specific biomarkers that are indicative of ASD, utilizing advanced computer algorithms to generate a risk score. This innovative testing solution aims to facilitate early intervention services, which are crucial for improving language, social skills, and cognitive development in affected children. BioROSA primarily targets healthcare providers, including pediatricians and specialists in developmental disorders, who serve parents and caregivers concerned about the developmental health of their children. The company's product is designed for use in markets across the United States and beyond, addressing a significant gap in the available diagnostic tools for ASD.BioROSA Technologies has established a revenue model centered around the sale of its flagship blood test for ASD detection. The company engages in direct-to-consumer transactions as well as partnerships with healthcare providers, creating a structured framework for delivering its services to end users. Clients, such as hospitals and pediatric clinics, may order the test and subsequently provide results to parents, who play a key role in the decision-making process regarding potential early intervention strategies. The pricing structure for the BioROSA test is designed to ensure accessibility for institutions, allowing for broader adoption of the technology within the healthcare community. This comprehensive approach fosters ongoing relationships with healthcare providers and supports the company's mission of transforming ASD diagnosis and treatment.BioROSA Technologies plans to leverage the recent funding of USD 0.45 mn from July 2019 to enhance product development and market penetration. The company is focused on expanding its offerings in the ASD diagnostic space and aims to enter new geographic markets beyond the United States. Specific plans for upcoming products and geographic expansions are currently under development, with the company aiming for a broader reach by 2023.

## Funding rounds

- Seed, Jun 14, 2018 — SOSV

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed